35 POSTER A Phase I trial of a combination of the mToR Inhibitor Everolimus (RAD001) and two schedules of the vascular endothelial growth factor (VEGF) receptor tyrosine kinase inhibitor Vatalanib (PTK787/ZK222584) in patients (pts) with advanced solid tumors

✍ Scribed by G. Dy; G. Croghan; A. Furth; J. Reid; L. Hanson; M. Roos; A. Tan; A. Adjei

• Book ID: 118623664
• Publisher: Elsevier Science
• Year: 2006
• Tongue: English
• Weight: 134 KB
• Volume: 4
• Category: Article
• ISSN: 1359-6349
• DOI: 10.1016/s1359-6349(06)70041-6